Get the Stockscreener App
6.02
3.26%
0.19
Myriad Genetics Inc stock is traded at $6.02, with a volume of 1.01M.
It is up +3.26% in the last 24 hours and up +31.15% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$5.83
Open:
$5.85
24h Volume:
1.01M
Relative Volume:
0.53
Market Cap:
$560.13M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-4.6308
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+5.43%
1M Performance:
+31.15%
6M Performance:
-57.55%
1Y Performance:
-78.24%
1-Day Range:
$5.805
$6.105
1-Week Range:
$5.225
$6.105
52-Week Range:
$3.76
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.02 | 531.28M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Opendoor, SmartRent, Myriad Genetics, Reddit, and Unity Stocks Trade Down, What You Need To Know - Yahoo Finance
ANGLE CEO on breakthrough liquid biopsy partnership with Myriad Genetics - Proactive Investors
Angle teams up with Myriad Genetics on cancer patient blood testing - MarketScreener
ANGLE plc partners with Myriad Genetics to advance cancer diagnostics - MSN
ANGLE partners with Myriad Genetics on enhanced patient treatment approach in cancer - Proactive financial news
ANGLE's Collaboration with Myriad Genetics: A Game-Changer in Liquid Biopsy and Precision Oncology - AInvest
ANGLE Announces Collaboration with Myriad Genetics - Yahoo Finance
Breakthrough in Cancer Testing: ANGLE and Myriad Genetics Join Forces for Blood-Based Diagnostic Solution - Stock Titan
Myriad Genetics Appoints Ben R. Wheeler as CFO - MSN
Myriad Genetics announces CFO appointment - MSN
Can Myriad Genetics Inc. Regain Momentum After BreakdownJuly 2025 News Drivers & Accurate Entry/Exit Alerts - newsimpact.co.kr
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Myriad Genetics appoints Ben Wheeler chief financial officer - MarketScreener
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer - TradingView
Leadership Continuity and Strategic Execution at Myriad Genetics: A Case for Stability in a High-Growth Sector - AInvest
Myriad Genetics, Inc. Announces Chief Financial Officer Changes - MarketScreener
Myriad Genetics appoints Ben Wheeler as Chief Financial Officer - TipRanks
Leadership Continuity and Compensation Alignment at Myriad Genetics: Assessing Ben Wheeler's Strategic Promotion for Long-Term Shareholder Value - AInvest
After 13 Years at Company: Myriad Genetics Elevates Operations Finance Chief Ben Wheeler to Global CFO Position - Stock Titan
Is Myriad Genetics Inc. a top pick in the sectorJuly 2025 News Drivers & High Accuracy Buy Signal Tips - newsimpact.co.kr
3 Healthcare Stocks We’re Skeptical Of - FinancialContent
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st
Myriad Genetics Inc. Bounces Off Moving Average SupportPortfolio Gains Report & Low Drawdown Investment Ideas - classian.co.kr
Will Myriad Genetics Inc. Hold Gains Into CloseQuarterly Market Review & Technical Buy Zone Confirmations - newsimpact.co.kr
Is Myriad Genetics Inc. in accumulation or distribution phase2025 Earnings Impact & Long Hold Capital Preservation Plans - newsyoung.net
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) - MSN
Myriad Genetics Inc. At Decision Level — Rebound or ResistanceJobs Report & Daily Volume Surge Signals - thegnnews.com
Myriad Genetics Inc. Consolidation Zone May Signal Accumulation2025 Trade Ideas & Entry Point Confirmation Signals - newsyoung.net
Myriad Genetics Inc. Inches Above Key Support — Safe to HoldJuly 2025 Earnings & Smart Allocation Stock Tips - thegnnews.com
New Myriad Genetics Survey Uncovers Women Fear Screenings--But F - GuruFocus
Myriad Genetics Reveals Insights from Cancer Risk Survey Highlighting Women's Attitudes Toward Health Screenings - Quiver Quantitative
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results - GlobeNewswire
Women Want Cancer Genetic Testing But Fear Results: New Health Survey Reveals Critical Gap - Stock Titan
MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance - Yahoo Finance
Myriad Genetics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Earnings Release: Here's Why Analysts Cut Their Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target To US$10.54 - 富途牛牛
10 Best 52-Week Low Penny Stocks to Buy Now - Insider Monkey
Will Myriad Genetics Inc. rebound enough to break evenShort-Term Stock Trend Forecast Guide - Newser
What’s next for Myriad Genetics Inc. stock priceHigh Return Trade Roadmap with Setup Filters - Newser
Is Myriad Genetics Inc. meeting your algorithmic filter criteriaScalable Strategy with Chart Confirmation - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedBuy Candidate Summary Based on Fundamentals - Newser
Myriad Genetics Raises FY25 Revenue and EBITDA Forecasts, Exceeding Market Consensus - AInvest
Myriad Genetics shares fall 1.48% premarket after UBS lowered its price target to $6. - AInvest
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics 2025 Q2 Earnings Misses Targets as Net Loss Widens 800.5% - AInvest
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates - MSN
CareDx Names Nathan Smith as New CFO - AInvest
Myriad Genetics Reports 1% YoY Revenue Growth in Q2 2025 - AInvest
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):